More than 500 people with bipolar disease die each day from suicidal crisis across the OECD countries. NeuroRx has demonstrated human proof of concept for a first-in-class, rapid-onset, sustained therapy for this condition, which currently has no approved treatment.
Jonathan C. Javitt, M.D., M.P.H. is an international expert in Pharmaceutical and MedDevice development, and Health IT. He has played a leading role in six startups with successful public exits and been appointed to leadership positions by 3 US Presidents.